MADtech Brokerage Event

29–30 Oct 2025 | Madrid, Spain

InvestmentUpdated on 21 October 2025

Advanced Therapies for liver diseases

CEO at Servatrix

Madrid, Spain

About

Liver fibrosis in the form of MASH is the most common liver disorder worldwide, will affect approximately 25% of world´s population (1 in 4)
TAM of 27 B
Currently, only one drug has received provisional FDA approval for MASH after 1 year of clinical trial. with some concerns: results after completion of the 5-year clinical trial / optimization of dosing and timing / long term safety / very expensive / not covered by Health Systems for a chronic treatment
But oru approach in totally new, Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that regulates the expression of multiple defensive genes.NRF2 makes heterodimers with small MAFs and activates genes containing the Antioxidant response Element (ARE).

Organisation

Servatrix

SME/Start-up

Madrid, Spain

Similar opportunities